Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Prochlorperazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 9/20 | 0.82 |
| ▸ | LMNA | P02545 | 8/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 6/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | GMNN | O75496 | 3/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.82 |
| ▸ | ADRA2A | P08913 | 7/20 | 0.82 |
| ▸ | ADRA2C | P18825 | 7/20 | 0.82 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.82 |
| ▸ | HTR2A | P28223 | 7/20 | 0.82 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.82 |
| ▸ | HRH1 | P35367 | 7/20 | 0.82 |
| ▸ | DRD3 | P35462 | 7/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prochlorperazine SCHEMBL8911628 | 1.00 | LMNA (1.00) | LMNAMAPTMAPK1SMN1; SMN2NPSR1 | |
| Prochlorperazine SCHEMBL29686418 | 1.00 | LMNA (1.00) | LMNAMAPTMAPK1SMN1; SMN2NPSR1 | |
| Prochlorperazine SCHEMBL8914157 | 1.00 | LMNA (1.00) | LMNAMAPTMAPK1SMN1; SMN2NPSR1 | |
| Prochlorperazine SCHEMBL29634451 | 1.00 | LMNA (1.00) | LMNAMAPTMAPK1SMN1; SMN2NPSR1 | |
| Prochlorperazine SCHEMBL718254 | 1.00 | LMNA (1.00) | LMNAMAPTMAPK1SMN1; SMN2NPSR1 | |
| Prochlorperazine SCHEMBL5494383 | 1.00 | LMNA (1.00) | LMNAMAPTMAPK1SMN1; SMN2NPSR1 | |
| Prochlorperazine SCHEMBL40755 | 1.00 | LMNA (1.00) | LMNAMAPTMAPK1SMN1; SMN2NPSR1 | |
| Prochlorperazine SCHEMBL40756 | 1.00 | LMNA (1.00) | LMNAMAPTMAPK1SMN1; SMN2NPSR1 | |
| Prochlorperazine SCHEMBL28763049 | 0.95 | LMNA (0.91) | LMNAMAPTMAPK1SMN1; SMN2NPSR1 | |
| Perphenazine SCHEMBL871706 | 0.92 | MAPT (0.85) | LMNAMAPTMAPK1SMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109152702-A | COMPOSITIONS FOR TOPICAL APPLICATION OF COMPOUNDS | 伊拉斯吹斯制药有限公司 | 2019-01-04 | — | — | CN | disclosed |
| US-8771724-B2 | Percutaneous absorption enhancer and transdermal preparation using the same | TOA EIYO LTD. (JP) | 2014-07-08 | — | — | US | disclosed |
| US-8163475-B2 | Methods for diagnosis and prognosis of psychotic disorders | THE MCLEAN HOSPITAL CORPORATION (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110104241-A1 | PERCUTANEOUS ABSORPTION ENHANCER AND TRANSDERMAL PREPARATION USING THE SAME | TOA EIYO LTD. (JP) | 2011-05-05 | — | — | US | disclosed |
| US-20100249032-A1 | Human EPO Mimetic Hinge Core Mimetibodies, Compositions, Methods and Uses | HEAVNER GEORGE A | 2010-09-30 | — | — | US | disclosed |
| US-6780504-B2 | COVERING, ACTIVE MATERIAL AND ADHESIVE; SPRAYING | GRUENENTHAL GMBH (DE) | 2004-08-24 | — | — | US | disclosed |
| US-20020142036-A1 | Covering, active material and adhesive; spraying | GRUENENTHAL GMBH (DE) | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249032-A1 | Human EPO Mimetic Hinge Core Mimetibodies, Compositions, Methods and Uses | EPOR, GHITM, HBB | DRD2 4675/4885LMNA 2395/4885MAPT 3023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.